Fitbit and Quest Diagnostics have announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences the risk of developing several diseases, including diabetes and heart disease.
Tag Archive for: Diabetes
“We are very pleased with the agreement to acquire the three Catalent manufacturing sites which will enable us to serve significantly more people living with diabetes and obesity in the future,“ said Lars Fruergaard Jørgensen, president and chief executive officer at Novo Nordisk.
Animal and early-stage human trial data for Amgen’s experimental obesity drug published in a medical journal showed that it promoted significant weight loss with an acceptable safety profile, the company said on Monday.
Novo Nordisk will target launches of its mega popular obesity shot Wegovy in markets where it already has strong sales of its older weight-loss drug Saxenda, CEO Lars Fruergaard Jorgensen said, as it faces growing competition from U.S. rival Eli Lilly.
Stringent regulation, manufacturing costs and absence of price control contribute to high GLP-1 agonist costs in the U.S. Patients could go to other countries for cheaper treatment.
The persistent shortage of genuine glucagon-like peptide 1 receptor agonist products has led to an increase in fake versions, the World Health Organization warned on Monday.
Lexington, Massachusetts-based Fractyl Health develops “disease-modifying” therapies that target organ-level root causes to treat metabolic diseases like type-2 diabetes and obesity.
According to Spiegel magazine, Lilly is in talks with the German government to try to end a ban on the public health system paying for weight-loss treatments.
According to the FDA’s website, the limit, which is in place through February, is due to an increase in demand.
As JPM week drew to a close, Lilly CEO David Ricks discussed what he sees in store for the biopharma industry.
